UFP Technologies, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. Financial amounts below are in U.S. dollars; amounts are shown in millions unless noted. The company designs and manufactures engineered products, with medical products its largest market, and reports one operating segment.
Financial performance
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Net sales | $100.8 | $97.0 | $298.6 | $262.6 |
| Gross profit | $27.8 | $25.5 | $86.1 | $67.0 |
| Gross margin | 27.5% | 26.3% | 28.8% | 25.5% |
| Operating income | $15.0 | $26.0 | $44.9 | $44.5 |
| Net income | $11.7 | $19.5 | $33.3 | $33.3 |
| Diluted EPS | $1.52 | $2.56 | $4.33 | $4.37 |
- Q3 sales increased 3.9% year over year; medical-market sales rose 6.8%. Nine-month sales increased 13.7%, including reported medical-market growth of 34.0%.
- Management attributed improved gross margin to operating efficiencies and a higher-margin business mix. Nine-month SG&A increased 11.4% to $37.8 million, primarily from compensation and benefits and Advant acquisition-related expenses.
- Operating cash flow was $28.6 million for the first nine months, compared with cash used of $0.1 million in the prior-year period. Capital expenditures were $7.7 million. Cash and equivalents were $6.4 million at quarter-end, up from $4.5 million at December 31, 2022.
- At September 30, debt was $43.0 million ($10.0 million revolving borrowings and $33.0 million term loan); $39.0 million was classified as long-term. The applicable borrowing rate was approximately 6.6%. The company reported compliance with its debt covenants. Current debt maturities are $4.0 million in 2024 and $4.0 million in 2025; most remaining debt is due in 2026.
- Working capital increased: inventory rose to $69.8 million from $53.5 million at year-end, and net receivables rose to $61.0 million from $55.1 million. The company cited inventory building for expected demand and restocking.
Changes, unusual items, and management commentary
- Reported Q3 operating income and net income were lower than in Q3 2022, but the comparison includes a $15.6 million gain on the sale of the Molded Fiber business in 2022. Nine-month 2022 results also included that gain and a $6.2 million gain on fixed-asset sales. These items materially affect reported year-over-year comparisons.
- Fair-value remeasurement of DAS Medical contingent consideration generated expense of $0.2 million in Q3 and $3.3 million for the nine months of 2023. The company paid $5.0 million against contingent consideration during Q2; the recorded liability was approximately $12.9 million at September 30.
- Net interest expense rose to $2.9 million for the nine months from $1.9 million, primarily due to higher interest rates. The nine-month effective tax rate fell to 20.7% from 22.4%, which management attributed largely to anticipated foreign tax credits. Management cautioned that the effective tax rate may be volatile.
- The medical market represented 86.5% of Q3 sales and 86.1% of nine-month sales. One customer represented 30.3% of Q3 revenue and 24.7% of nine-month revenue, indicating significant customer concentration.
- Management plans to add manufacturing capacity and pursue organic growth and potentially complementary acquisitions. It expects cash from operations and available credit resources to fund requirements, including capital spending, for the next twelve months, but gave no specific revenue or earnings guidance. The company noted that future cash generation and access to financing are not assured.
Risks and contingencies
- Key disclosed risks include acquisition execution and integration, customer demand and new program launches, manufacturing efficiency and capacity expansion, debt and covenant compliance, and the availability and cost of financing.
- The credit agreement has a $90 million revolving facility within a $130 million total commitment; the company had $10.0 million drawn on the revolver and approximately $0.7 million in standby letters of credit outstanding. The filing reports covenant compliance at quarter-end.
- The filing reports no material litigation, no material changes to previously disclosed risk factors, and no material changes in market risk. The $2.6 million escrow related to the 2022 Molded Fiber sale was scheduled for release in January 2024, subject to claims and other agreement terms.
Important facts for investors to verify
- Underlying earnings and margins after accounting for the 2022 divestiture and fixed-asset gains and the 2023 contingent-consideration remeasurement.
- Whether elevated inventory converts into sales and cash, and whether receivables collection and operating cash flow remain strong.
- Medical-market growth, customer concentration, and the impact of the largest customer on future revenue.
- Debt repayment, interest costs, covenant headroom, contingent-consideration payments, and available revolver capacity.
- Progress and returns from planned capacity investments, and whether expected demand and management’s twelve-month liquidity assessment are realized.